(−)‐Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.